CLINICAL ROLE -
Use of Lutetium Lu-177 Vipivotide Tetraxetan to Treat Metastatic Castration-Resistant Prostate Cancer
The FDA-approved, targeted radiopharmaceutical agent can contribute to a patient’s cumulative radiation exposure.
Read More